BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

83 related articles for article (PubMed ID: 8636767)

  • 1. Vinblastine, bleomycin, and methotrexate chemotherapy plus extended-field radiotherapy in early, favorably presenting, clinically staged Hodgkin's patients: the Gruppo Italiano per lo Studio dei Linfomi Experience.
    Gobbi PG; Pieresca C; Frassoldati A; Carotenuto M; Di Renzo N; La Sala A; Berté R; Avanzini P; Federico M; Silingardi V; Ascari E
    J Clin Oncol; 1996 Feb; 14(2):527-33. PubMed ID: 8636767
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Vinblastine, bleomycin, and methotrexate chemotherapy plus irradiation for patients with early-stage, favorable Hodgkin lymphoma: the experience of the Gruppo Italiano Studio Linfomi.
    Gobbi PG; Broglia C; Merli F; Dell'Olio M; Stelitano C; Iannitto E; Federico M; Bertè R; Luisi D; Molica S; Cavalli C; Dezza L; Ascari E
    Cancer; 2003 Dec; 98(11):2393-401. PubMed ID: 14635074
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CCNU, vinblastine, procarbazine and prednisone (CVPP) with extended-field radiotherapy in the treatment of early unfavorable Hodgkin's disease. A prospective study on behalf of the Gruppo Italiano per lo Studio dei Linfomi (GISL).
    Gobbi PG; Pieresca C; Cavanna L; Corbella F; Vallisa D; Federico M; Formisano R; Carotenuto M; Merli F; Callea V; Angrilli F; Silingardi V
    Haematologica; 1996; 81(6):503-12. PubMed ID: 9009437
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and toxicity of vinblastine, bleomycin, and methotrexate with involved-field radiotherapy in clinical stage IA and IIA Hodgkin's disease: a British National Lymphoma Investigation pilot study.
    Bates NP; Williams MV; Bessell EM; Vaughan Hudson G; Vaughan Hudson B
    J Clin Oncol; 1994 Feb; 12(2):288-96. PubMed ID: 7509382
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Stanford-Kaiser Permanente G1 study for clinical stage I to IIA Hodgkin's disease: subtotal lymphoid irradiation versus vinblastine, methotrexate, and bleomycin chemotherapy and regional irradiation.
    Horning SJ; Hoppe RT; Mason J; Brown BW; Hancock SL; Baer D; Rosenberg SA
    J Clin Oncol; 1997 May; 15(5):1736-44. PubMed ID: 9164180
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bulky mediastinal Hodgkin's disease: results of a combined modality approach (ABVD/MOPP alternating chemotherapy plus radiation therapy).
    De Lena M; Ditonno P; Lorusso V; Timurian A; Pellecchia A; Brandi M; Berardi F; Marzullo F
    Haematologica; 1993; 78(4):230-5. PubMed ID: 7507457
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Vinblastine, bleomycin, and methotrexate: an effective adjuvant in favorable Hodgkin's disease.
    Horning SJ; Hoppe RT; Hancock SL; Rosenberg SA
    J Clin Oncol; 1988 Dec; 6(12):1822-31. PubMed ID: 2462025
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of vinblastine, bleomycin, methotrexate (VBM) combination chemotherapy with involved field radiotherapy in early stage (I-IIA) Hodgkin disease patients.
    Martinelli G; Cocorocchio E; Saletti PC; Orecchia R; Bernier J; Tradati N; Santoro P; Robertson C; Peccatori FA; Zucca E; Cavalli F
    Leuk Lymphoma; 2003 Nov; 44(11):1919-23. PubMed ID: 14738143
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bleomycin, epidoxorubicin, cyclophosphamide, vincristine and prednisone (BACOP) in patients with follicular non-Hodgkin's lymphoma: results of a prospective, multicenter study of the Gruppo Italiano Per Lo Studio Dei Linfomi (GISL).
    Lombardo M; Morabito F; Merli F; Molica S; Cavanna L; Sacchi S; Broglia C; Angrilli F; Ilariucci F; Stelitano C; Luisi D; Bertè R; Luminari S; Federico M; Brugiatelli M;
    Leuk Lymphoma; 2002 Sep; 43(9):1795-801. PubMed ID: 12685834
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Relapse and late complications in early-stage Hodgkin's disease patients with mediastinal involvement treated with radiotherapy alone or plus one cycle of ABVD.
    Enrici RM; Anselmo AP; Donato V; Falchetto Osti M; Santoro M; Tombolini V; Mandelli F
    Haematologica; 1999 Oct; 84(10):917-23. PubMed ID: 10509040
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of the VBM regimen in the treatment of elderly patients with Hodgkin's disease.
    Zinzani PL; Magagnoli M; Bendandi M; Barbieri E; Galuppi A; Gherlinzoni F; Tani M; Albertini P; Stefoni V; Babini L; Tura S
    Haematologica; 2000 Jul; 85(7):729-32. PubMed ID: 10897125
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tumour burden at diagnosis as the main clinical predictor of cell resistance in patients with early stage, favourable Hodgkin lymphoma treated with VBM chemotherapy plus radiotherapy.
    Gobbi PG; Bergonzi M; Bassi E; Merli F; Coriani C; Federico M
    Hematol Oncol; 2013 Sep; 31(3):151-5. PubMed ID: 23108910
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rapidly alternating COPP/ABV/IMEP is not superior to conventional alternating COPP/ABVD in combination with extended-field radiotherapy in intermediate-stage Hodgkin's lymphoma: final results of the German Hodgkin's Lymphoma Study Group Trial HD5.
    Sieber M; Tesch H; Pfistner B; Rueffer U; Lathan B; Brosteanu O; Paulus U; Koch T; Pfreundschuh M; Loeffler M; Engert A; Josting A; Wolf J; Hasenclever D; Franklin J; Duehmke E; Georgii A; Schalk KP; Kirchner H; Doelken G; Munker R; Koch P; Herrmann R; Greil R; Anselmo AP; Diehl V
    J Clin Oncol; 2002 Jan; 20(2):476-84. PubMed ID: 11786577
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MOPP/EBV/CAD hybrid chemotherapy with or without limited radiotherapy in advanced or unfavorably presenting Hodgkin's disease: a report from the Italian Lymphoma Study Group.
    Gobbi PG; Pieresca C; Federico M; Di Renzo N; Narni F; Iannitto E; Grignani G; Cavanna L; Avanzini P; Partesotti G
    J Clin Oncol; 1993 Apr; 11(4):712-9. PubMed ID: 7683044
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Two cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine plus extended-field radiotherapy is superior to radiotherapy alone in early favorable Hodgkin's lymphoma: final results of the GHSG HD7 trial.
    Engert A; Franklin J; Eich HT; Brillant C; Sehlen S; Cartoni C; Herrmann R; Pfreundschuh M; Sieber M; Tesch H; Franke A; Koch P; de Wit M; Paulus U; Hasenclever D; Loeffler M; Müller RP; Müller-Hermelink HK; Dühmke E; Diehl V
    J Clin Oncol; 2007 Aug; 25(23):3495-502. PubMed ID: 17606976
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Involved-field radiotherapy is equally effective and less toxic compared with extended-field radiotherapy after four cycles of chemotherapy in patients with early-stage unfavorable Hodgkin's lymphoma: results of the HD8 trial of the German Hodgkin's Lymphoma Study Group.
    Engert A; Schiller P; Josting A; Herrmann R; Koch P; Sieber M; Boissevain F; De Wit M; Mezger J; Duhmke E; Willich N; Muller RP; Schmidt BF; Renner H; Muller-Hermelink HK; Pfistner B; Wolf J; Hasenclever D; Loffler M; Diehl V;
    J Clin Oncol; 2003 Oct; 21(19):3601-8. PubMed ID: 12913100
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Response-guided ABVD chemotherapy plus involved-field radiation therapy for intermediate-stage Hodgkin lymphoma in the pre-positron emission tomography era: a Gruppo Italiano Studio Linfomi (GISL) prospective trial.
    Iannitto E; Minardi V; Gobbi PG; Calvaruso G; Tripodo C; Marcheselli L; Luminari S; Merli F; Baldini L; Stelitano C; Callea V; Petrini M; Angrilli F; Quarta G; Vallisa D; Molica S; Liardo E; Polimeno G; Brugiatelli M; Federico M
    Clin Lymphoma Myeloma; 2009 Apr; 9(2):138-44. PubMed ID: 19406724
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prospective study of combined modality treatment or radiotherapy alone in the management of early-stage adult Hodgkin's disease.
    Yildiz F; Zengin N; Engin H; Güllü I; Barista I; Caglar M; Ozyar E; Cengiz M; Gürkaynak M; Zorlu F; Caner B; Atahan IL; Tekuzman G
    Int J Radiat Oncol Biol Phys; 2004 Nov; 60(3):839-46. PubMed ID: 15465201
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of patients with advanced or bulky Hodgkin disease with a 12-week doxorubicin, bleomycin, vinblastine, and dacarbazine-like chemotherapy regimen followed by extended-field, full-dose radiotherapy: long-term results of the Groupe Ouest et Est des Leucémies et Autres Maladies de Sang H90-A/B Multicenter Randomized Trial.
    Djeridane M; Oudard S; Escoffre-Barbe M; Lacotte-Thierry L; Desablens B; Briére J; Dib M; Cassasus P; Ghandour C; Lamy T; Lejeune F; Simon M; Traullé C; Vigier M; Maisonneuve H; Briére J; Colonna P; Andrieu JM
    Cancer; 2002 Nov; 95(10):2169-79. PubMed ID: 12412171
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Brief chemotherapy, Stanford V, and adjuvant radiotherapy for bulky or advanced-stage Hodgkin's disease: a preliminary report.
    Bartlett NL; Rosenberg SA; Hoppe RT; Hancock SL; Horning SJ
    J Clin Oncol; 1995 May; 13(5):1080-8. PubMed ID: 7537796
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.